Core Viewpoint - The stock of Xinhua Medical (600587) has shown a decline in both share price and financial performance, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of October 30, 2025, Xinhua Medical's stock closed at 16.01 yuan, down 1.17% with a trading volume of 107,600 hands and a turnover of 173 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 2.188 billion yuan, a year-on-year decrease of 2.2%, and a net profit attributable to shareholders of 48.59 million yuan, down 63.39% year-on-year [3]. - For the first three quarters of 2025, the main revenue was 6.978 billion yuan, down 6.0%, and the net profit was 434 million yuan, down 29.61% [3]. Market Position - Xinhua Medical's total market capitalization is 9.713 billion yuan, with a net asset value of 8.164 billion yuan and a net profit of 434 million yuan, ranking 38th, 11th, and 15th respectively in the medical device industry [3]. - The company's price-to-earnings ratio (P/E) is 16.77, significantly lower than the industry average of 60.08, ranking 5th in the industry [3]. Investment Sentiment - In the last 90 days, two institutions have given a rating of "buy" for Xinhua Medical, with an average target price of 19.7 yuan [4].

证券代码：600587 证券简称：新华医疗 编号：临 2025-053 山东新华医疗器械股份有限公司 第十一届董事会第二十二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第二十二次会议于 2025 年 10 月 18 日以书面或通讯方式通知全体董 事，据此通知，会议于 2025 年 10 月 29 日在公司三楼会议室召开。会议以现场 与通讯相结合的方式召开，会议应到董事 11 名，实到 11 名，公司高级管理人员 列席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司 章程》的规定。 二、董事会会议审议情况 表决结果：同意 11 票，反对 0 票，弃权 0 票。 （二）审议通过《关于换选第十一届董事会各专门委员会委员的议案》 因公司董事会成员发生变动，公司拟对第十一届董事会各专门委员会委员 进行换选，具体换选情况如下： 1、推举吴晓辉先生、王玉全先生、姜丽勇先生、黎元先生四位董事担任审 计委员会委员，选举吴晓辉先生 ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-057 山东新华医疗器械股份有限公司 关于回购注销部分限制性股票减资暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原因 山东新华医疗器械股份有限公司(以下简称"公司"或"新华医疗")于 2025 年 10 月 29 日召开第十一届董事会第二十二次会议，审议通过了《关于调整 2021 年限制性股票激励计划回购价格及回购数量的议案》和《关于回购注销部分限制 性股票的议案》，同意公司以自有资金回购注销《2021 年限制性股票激励计划》 （以下简称"《激励计划》"）中 6 名激励对象已获授但尚未解除限售的限制性股 票合计 33,370 股。上述回购注销实施完毕后，公司总股本由 606,677,919 股减 少至 606,644,549 股，注册资本由人民币 606,677,919 元减少至 606,644,549 元（具体以实际核准的注销股数为准）。 具 体 内 容 详 见 公 司 2025 年 10 月 31 日 于 上 ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-055 山东新华医疗器械股份有限公司 关于回购注销部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司(以下简称"公司"或"新华医疗") 于 2025 年 10 月 29 日召开第十一届董事会第二十二次会议，审议通过了《关于回购注销 部分限制性股票的议案》，公司拟对《2021 年限制性股票激励计划（草案）》（以 下简称"《激励计划》"）中 6 名激励对象已获授但尚未解除限售的限制性股票合 计 33,370 股进行回购并注销，现将相关事项公告如下： 一、限制性股票激励计划批准及实施情况 1、2021 年 11 月 24 日，公司召开第十届董事会第十八次会议，审议通过了 《关于公司<2021 年限制性股票激励计划（草案）>及其摘要的议案》、《关于公 司<2021 年限制性股票激励计划实施考核管理办法>的议案》和《关于提请股东 大会授权董事会办理公司 2021 年限制性股票激励计划相关事宜的议案》。公司独 立董事就 ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-054 山东新华医疗器械股份有限公司 关于调整 2021 年限制性股票激励计划回购价格及回购数量的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司(以下简称"公司"或"新华医疗")于 2025 年 10 月 29 日召开第十一届董事会第二十二次会议，审议通过了《关于调整 2021 年限制性股票激励计划回购价格及回购数量的议案》，因公司利润分配方案已实 施完毕，根据公司《2021 年限制性股票激励计划（草案）》（以下简称"《激励计 划》"）的相关规定，应对 2021 年限制性股票激励计划（以下简称"本次激励计 划"）限制性股票回购价格及回购数量进行相应调整。现将相关事项公告如下： 一、本次激励计划批准及实施情况 1、2021 年 11 月 24 日，公司召开第十届董事会第十八次会议，审议通过了 《关于公司<2021 年限制性股票激励计划（草案）>及其摘要的议案》、《关于公 司<2021 年限制性股票激励计划实施考核管理办法 ...

关 于 山 东 新 华 医 疗 器 械 股 份 有 限 公 司 法 律 意 见 书 君致（ 法 ）字[2025]295 号 北 京 市 君 致 律 师 事 务 所 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编(100013) Add: 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC Tel: 010-52213236/7 www.junzhilawyer.com 北京市东城区 北三环东路 36 号环球贸易中 心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 回 购 注 销 2021 年 限 制 性 股 票 激 励 计 划 部 分 限 制 性 股 票 及 调 整 回 购 价 格 与 回 购 数 量 之 及调整回购价格与回购数量之法律意见书 君致法字 2025295 号 致：山东新华医疗器械股份有限公司 北京市君致律师事务所（以下简称"本所"）接受山东新华医疗器械股份有限 公 ...

一、关于调整 2021 年限制性股票激励计划回购价格及回购数量议案的独立意 见 公司本次激励计划回购价格及回购数量的调整符合《上市公司股权激励管理办 法》《2021 年限制性股票激励计划》（以下简称"《激励计划》"）及相关法律法 规的规定。本次回购价格及回购数量调整的审议程序合法合规，未损害公司及全体 股东的权益，不会对公司的财务状况和经营业绩产生影响。我们一致同意公司本次 激励计划回购价格的调整。 二、关于回购注销部分限制性股票议案的独立意见 公司本次回购注销部分限制性股票事项，符合《上市公司股权激励管理办法》 以及《激励计划》等有关文件的规定，董事会审议程序合法合规；公司本次回购注 销不影响公司持续经营，也不会损害公司及全体股东利益。我们一致同意公司本次 回购注销部分限制性股票相关事宜。 山东新华医疗器械股份有限公司独立董事 关于第十一届董事会第二十二次会议相关议案的独立意见 根据《公司法》、《证券法》、《上市公司独立董事规则》和《上海证券交易所股 票上市规则》以及《山东新华医疗器械股份有限公司章程》（以下简称"《公司章程》"） 等相关规定，我们作为山东新华医疗器械股份有限公司（以下简称"公司"）的独立 ...

山东新华医疗器械股份有限公司 章 程 二○二五年十月 | | | | | | | | | 山东新华医疗器械股份有限公司章程（2025） 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 充分发挥中国共产党山东新华医疗器械股份有限公司委员会（以下简称"公司党 委"）的领导核心与政治核心作用，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《中国共产党章 程》（以下简称《党章》）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"）。 公司以募集方式设立；在山东省工商行政管理局注册登记，取得营业执照， 统一社会信用代码 91370000267171351C。 公司经山东省淄博市经济体制改革委员会以淄体改股字〔1993〕83 号文批 准设立。《公司法》颁布实施后，公司对照《公司法》进行了规范，1996 年 12 月 30 日由山东省经济体制改革委员会以鲁体改函字〔1996〕255 号文予以确认， 并由山东省人民政府颁发了鲁政股字〔1996〕202 号《山东省股份有限公司批准 ...

Core Points - The company, Shandong Xinhua Medical Equipment Co., Ltd., announced a plan to repurchase and cancel 33,400 restricted shares due to certain incentive recipients no longer meeting the conditions [1][2] - The repurchase price is set at 7.55 yuan per share, totaling approximately 253,000 yuan [1][5] Summary by Sections Repurchase Cancellation Reason - The repurchase involves six incentive recipients, four of whom have changed jobs and two have retired, thus not meeting the conditions of the 2021 Restricted Stock Incentive Plan [2] Repurchase Quantity - The initial number of shares to be repurchased was 25,670, which was adjusted to 33,400 shares due to a capital reserve increase implemented in 2023 [3] Repurchase Price - The initial grant price was 11.26 yuan per share, which was adjusted to 7.55 yuan per share after multiple dividend distributions since 2021 [4] Funding Source and Amount - The repurchase will be funded by the company's own funds, with a total estimated amount of approximately 253,000 yuan [5] Decision Process - The company has completed necessary approvals and disclosures, with the board and supervisory committee approving the repurchase on October 29, 2025 [6] Impact on the Company - The repurchase will result in a minor reduction of total shares, reflecting the company's commitment to strict execution of the incentive plan and maintaining a stable equity structure [7]

Financial Performance - The company's operating revenue for the third quarter was CNY 2,187,552,954.52, a decrease of 6.00% compared to the same period last year[2] - Total profit for the third quarter was CNY 63,978,928.00, down 59.15% year-on-year[2] - Net profit attributable to shareholders was CNY 48,592,929.38, a decline of 63.39% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses for the third quarter was CNY 37,661,492.02, down 71.77% year-on-year[2] - Basic earnings per share for the third quarter were CNY 0.08, down 55.56% year-on-year[2] - Total operating revenue for the first three quarters of 2025 was CNY 6,977,967,842.53, a decrease of 6.0% compared to CNY 7,423,276,804.99 in the same period of 2024[14] - Net profit for the first three quarters of 2025 was CNY 444,084,027.69, a decline of 29.9% compared to CNY 633,953,374.65 in 2024[15] - Earnings per share for the first three quarters of 2025 was CNY 0.72, down from CNY 1.17 in the same period of 2024[15] - The total comprehensive income for the first three quarters of 2025 was CNY 433,285,359.54, compared to CNY 634,016,268.78 in 2024, a decrease of 31.7%[15] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 15,078,842,380.91, a decrease of 2.88% from the end of the previous year[3] - As of September 30, 2025, the total assets of Shandong Xinhua Medical Equipment Co., Ltd. amounted to CNY 15,078,842,380.91, a decrease from CNY 15,526,375,082.77 on December 31, 2024, representing a decline of approximately 2.9%[10] - Current assets totaled CNY 8,969,621,191.24, down from CNY 9,366,020,874.15, indicating a decrease of about 4.2%[11] - The total liabilities decreased to CNY 6,914,349,290.72 in 2025 from CNY 7,543,748,934.23 in 2024, reflecting a reduction of 8.3%[12] - Total equity attributable to shareholders increased by 3.08% to CNY 7,831,135,267.95 compared to the end of the previous year[3] - Total equity increased to CNY 8,164,493,090.19 in 2025, compared to CNY 7,982,626,148.54 in 2024, marking a growth of 2.3%[12] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 219,663,782.82, an increase of 707.49% compared to the previous year[2] - Operating cash flow for the first nine months was ¥219,663,782.82, a significant improvement from a negative cash flow of ¥36,159,027.91 in the same period last year[18] - Total cash inflow from operating activities decreased to ¥6,763,940,456.65, down from ¥7,182,115,065.89 year-over-year[18] - Cash outflow from operating activities also decreased to ¥6,544,276,673.83 compared to ¥7,218,274,093.80 in the previous year[18] - The ending cash and cash equivalents balance was ¥2,617,212,764.15, compared to ¥2,348,299,423.67 at the end of the same period last year[19] Investments and Expenses - The company experienced a significant reduction in other income and investment income, contributing to the decline in profits[6] - Research and development expenses increased to CNY 321,747,889.75 in 2025, up 8.3% from CNY 297,141,310.80 in 2024[14] - The company reported a decrease in sales expenses to CNY 627,531,352.26 in 2025 from CNY 641,583,248.14 in 2024, a reduction of 2.2%[14] - The company’s investment income for the first three quarters of 2025 was CNY 48,281,980.32, down from CNY 52,663,544.58 in 2024, a decline of 8.3%[14] Changes in Specific Accounts - Cash and cash equivalents were reported at CNY 2,751,625,610.03, a decrease from CNY 2,944,731,578.33, reflecting a decline of approximately 6.5%[10] - Accounts receivable increased to CNY 1,966,058,267.66 from CNY 1,879,527,944.98, marking an increase of about 4.6%[10] - Inventory decreased to CNY 3,141,146,365.93 from CNY 3,356,266,390.04, representing a decline of approximately 6.4%[11] - Short-term borrowings increased slightly to CNY 922,118,107.79 from CNY 900,609,472.27, an increase of about 2.8%[11] - Accounts payable decreased to CNY 2,301,442,182.11 from CNY 2,440,735,563.76, indicating a decline of approximately 5.7%[11] - Contract liabilities decreased to CNY 1,756,598,226.89 from CNY 2,049,292,887.66, reflecting a decrease of about 14.3%[11] - Long-term equity investments decreased to CNY 1,416,475,857.93 from CNY 1,506,671,275.58, a decline of approximately 6.0%[11] - The company reported a total non-current asset value of CNY 6,109,221,189.67, slightly down from CNY 6,160,354,208.62, indicating a decrease of about 0.8%[11] Asset Acquisitions and Disposals - The company paid ¥298,226,154.22 for the acquisition of fixed assets, an increase from ¥274,627,509.31 year-over-year[18] - The company reported a cash inflow of ¥99,870,479.75 from the disposal of subsidiaries and other business units[18] - The company received ¥12,405,032.46 from investment recoveries, a decrease from ¥125,983,225.85 in the previous year[18]